Rk Capital Management LLC Stake in Jazz Pharmaceuticals Plc (JAZZ) Increased by $8.84 Million

June 29, 2018 - By Noel Courtney

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate LogoBig Money Sentiment decreased to 1.02 in 2018 Q1. It has change of 0.07, from 2017Q4’s 1.09. The ratio worsened due to JAZZ positioning: 29 sold and 96 reduced. 44 funds bought stakes and 84 increased stakes. Investors holded 52.98 million in 2017Q4 but now own 51.95 million shares or 1.94% less. Sit Invest Associates owns 5,700 shs. Sei Invests reported 9,698 shs. 100 are held by Optimum Advisors. Morgan Stanley reported 0.01% of its capital in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Lpl Financial Limited Liability Company holds 4,801 shs or 0% of its capital. Rk Ltd Llc, a Colorado-based fund reported 104,900 shs. Caisse De Depot Et Placement Du Quebec invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Cadian Limited Partnership reported 1.21M shs or 9.88% of all its holdings. First Allied Advisory stated it has 0.11% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Northern holds 231,817 shs. Us National Bank & Trust De stated it has 1,153 shs or 0% of all its holdings. Ameriprise Fincl Inc, a Minnesota-based fund reported 174,360 shs. 6,335 were accumulated by Brown Capital Management. Citadel Advsrs Limited Liability has 0.01% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Winslow Evans And Crocker Incorporated reported 106 shs or 0% of all its holdings.

JAZZ had 23 sales and 0 insider purchases since January 12, 2018. This’s net activity of $5.86 million. The insider Young Matthew P. sold $233,789. On Thursday, June 14 $35,306 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was sold by MILLER MICHAEL PATRICK. The insider Treacy Paul sold 594 shs worth $84,030. On Friday, May 11 WILSON KAREN J also sold $620,400 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

In 2018Q1 SEC form is reported Rk Capital Management Llc’s holdings in Jazz Pharmaceuticals Plc (JAZZ) which was rose by 128.04%. The company’s stock rose 11.92% while stock markets declined as Rk Capital Management Llc bought 58,900 shares. The hedge fund is holding 104,900 shares, compared to the 46,000 from the previous quarter. And the reported value of the major pharmaceuticals company is $15.84 million for the 2018Q1. For a total of 154,234 shares it reduced its holding in Commercehub Inc by 224,585 shares in the quarter, and has cut its stake in Penn Natl Gaming Inc (NASDAQ:PENN).

For more Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news brought out recently go to: Benzinga.com, Streetinsider.com, Benzinga.com, Prnewswire.com or Prnewswire.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” brought out on June 20, 2018, “Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Cowen; ‘Transitioning Growth Asset'” on June 27, 2018, “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” with a publish date: June 21, 2018, “Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference” and the last “Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for …” with publication date: June 03, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

A total of 11 analysts rate Jazz Pharmaceuticals (NASDAQ:JAZZ) as follows: 10 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 91% are bullish. (NASDAQ:JAZZ) has 19 ratings reports on 29 Jun 2018 according to StockzIntelligence. On Friday, March 23 the company was maintained by H.C. Wainwright. On Wednesday, February 28 the stock has “Buy” rating by Cantor Fitzgerald. On Thursday, April 12 the firm has “Buy” rating given by Piper Jaffray. On Monday, April 30 Cantor Fitzgerald maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating. Cantor Fitzgerald has “Buy” rating and $20200 target. On Tuesday, January 2 the company was initiated by Leerink Swann. On Monday, May 7 Cantor Fitzgerald maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating. Cantor Fitzgerald has “Buy” rating and $20200 target. On Friday, April 6 the firm has “Buy” rating by Seaport Global given. On Friday, March 16 the firm has “Buy” rating given by Leerink Swann. In Tuesday, January 30 report Piper Jaffray maintained it with “Buy” rating and $194.0 target. On Monday, March 19 the stock has “Overweight” rating by Morgan Stanley.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.